Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.

Mylan (MYL) Obtains FDA Approval for Biosimilar of Humira

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira®...

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)

HERTFORDSHIRE, England and PITTSBURGH, July 7, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to...

Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection, Due to the Presence of Particulate

Los Angeles, California--(Newsfile Corp. - July 6, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V. ("Mylan" or "the Company") (NASDAQ: MYL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 16, 2016 and May 7, 2019, inclusive...

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Mylan NV said on Monday it would launch a generic version of Gilead Sciences' Covid-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

HERTFORDSHIRE, England and PITTSBURGH and BANGALORE, India, July 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the Drug Controller General of India (DCGI) has approved its remdesivir 100 mg/vial for restricted emergency use in India as part of the DCGI's...

Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 Patients

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws. To join the Mylan class action, go to http://www.rosenlegal.com/cases-register-1889.html or call Phillip

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Mylan N.V. Investors of Important August 25 Deadline in Securities Class Action – MYL

NEW YORK, July 3, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who purchased or...

MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors With Losses Exceeding $11,000,000 of Class Action and Lead Plaintiff Deadline: August 25, 2020

New York, New York--(Newsfile Corp. - July 2, 2020) -  Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mylan securities between February 16, 2016 and May 7, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...

MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors of Class Action and Lead Plaintiff Deadline: August 25, 2020

New York, New York--(Newsfile Corp. - July 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Mylan N.V. ("Mylan") (NASDAQ: MYL) between February 16, 2016 and May 7, 2019. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Western District of Pennsylvania. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mylan N.V. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 25, 2020 - MYL

Los Angeles, California--(Newsfile Corp. - July 1, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V. ("Mylan" or "the Company") (NASDAQ: MYL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 16, 2016 and May 7, 2019,...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, June 30, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"). The...

ROSEN, A LONGSTANDING AND TOP RANKED GLOBAL INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against Mylan N.V.; Encourages Investors with Losses in Excess of $100K to Contact the Firm  - MYL

HERTFORDSHIRE, England and PITTSBURGH, June 30, 2020 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company's extraordinary general meeting of...

Mylan Shareholders Overwhelmingly Approve Proposed Combination with Upjohn

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Mylan investors under the federal securities laws. To join the Mylan class action, go to http://www.rosenlegal.com/cases-register-1889.html or call Phillip Kim, Esq. toll-free at 866-767-3

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Mylan N.V. – MYL

Pfizer

Sanofi

Hydroxychloroquine as a COVID-19 treatment has been a controversial subject -- and the debate continues.

Is Hydroxychloroquine a Cure for COVID-19?

Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.

Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent

HERTFORDSHIRE, England and PITTSBURGH, June 18, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description. The...

Mylan Wins District Court Decision Against Biogen's Tecfidera® Patent

Gilead Sciences

Teva Pharmaceutical

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

Novartis

The agency found no evidence to support the theory that the antimalarial drugs touted by President Trump are effective against the coronavirus.

FDA Revokes Emergency Use Authorization for Hydroxychloroquine and Chloroquine as COVID-19 Treatments

The FDA revoked emergency use of the malaria drug hydroxychloroquine for COVID-19 on Monday.

FDA Revokes Emergency Use Status Of Trump-Touted Malaria Drug Hydroxychloroquine

Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

Mylan (MYL) and partner Biocon gains FDA approval for diabetes treatment, Semglee.

Mylan & Biocon's Semglee Wins FDA Approval for Diabetes

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 11, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Semglee™...

Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

Mylan (MYL) Up 13.7% Since Last Earnings Report: Can It Continue?

Endo International

TherapeuticsMD

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.

News for Mylan Stock (MYL)